
Novavax says Covid-19 vaccine shows 90.4% overall efficacy in US/Mexico Phase 3 trial
The American biotechnology company Novavax announced on Monday that its coronavirus vaccine candidate was found to have an overall efficacy of 90.4%…
Continue Reading